Verastem (VSTM) Free Cash Flow Growth (1y) (2012 - 2026)

Verastem (VSTM) Free Cash Flow Growth (1y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 7.12%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 1,092.51%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 66.37%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 3.98%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Verastem 607.94 Mn 410.11 Mn 15.90 Mn -34.75%

Historic Data

Download Data
DateValue
Mar 31, 2026 -34.75%
Dec 31, 2025 -19.34%
Sep 30, 2025 -52.20%
Jun 30, 2025 -18.38%
Mar 31, 2025 -36.60%
Dec 31, 2024 15.44%
Sep 30, 2024 -43.44%
Jun 30, 2024 -38.62%
Mar 31, 2024 -39.57%
Dec 31, 2023 -78.63%
Sep 30, 2023 -9.99%
Jun 30, 2023 -56.80%
Mar 31, 2023 -5.21%
Dec 31, 2022 -67.28%
Sep 30, 2022 -39.30%
Jun 30, 2022 5.44%
Mar 31, 2022 1.19%
Dec 31, 2021 54.23%
Sep 30, 2021 -124.21%
Jun 30, 2021 40.44%